| Phase 110 trials |
|
Phase 1
|
NCT07232589 |
Dec 2025 → May 2026 |
— |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06442436 |
Jul 2024 → Sep 2026 expected |
— |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06625827 |
Nov 2023 → Jan 2024 |
— |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06688045 |
Oct 2023 → Jan 2024 |
— |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06772818 |
Oct → Dec 2023 |
— |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06586671 |
Aug → Nov 2023 |
hematopoietic and lymphoid cell neoplasm |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06698016 |
Jul → Oct 2023 |
— |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06772805 |
Jul → Dec 2023 |
— |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05673460 |
Feb 2023 → Apr 2025 |
neoplasm of mature B-cells |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05347225 |
Jun 2022 → Apr 2027 expected |
hematopoietic and lymphoid cell neoplasm |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT03162536 |
Jun 2017 → Sep 2027 expected |
Richter transformation, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma +3 |
ArQule, Inc. |
Active not recruiting
|
No outcome recorded
|
| Phase 210 trials |
|
Phase 2
|
NCT07583810 |
Dec 2026 → May 2028 expected |
gastric mucosa-associated lymphoid tissue lymphoma, nodal marginal zone B-cell lymphoma, primary lymphoma of the conjunctiva, splenic marginal zone lymphoma |
City of Hope Medical Center |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07690891 |
Oct 2026 → Dec 2029 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Medical College of Wisconsin |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07557056 |
Sep 2026 → Dec 2027 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Jennifer Woyach |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06863402 |
Aug 2026 → Jun 2029 expected |
B-cell chronic lymphocytic leukemia, Richter transformation, diffuse large B-cell lymphoma |
Roswell Park Cancer Institute |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07194980 |
Aug 2026 → Oct 2029 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Fred Hutchinson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07673367 |
Jul 2026 → Jul 2031 expected |
mantle cell lymphoma |
Vanderbilt-Ingram Cancer Center |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07464210 |
Jun 2026 → Aug 2029 expected |
Waldenstrom macroglobulinemia |
Seoul National University Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06572618 |
Jan 2025 → Jan 2027 expected |
mantle cell lymphoma |
City of Hope Medical Center |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05458297 |
Jul 2022 → May 2029 expected |
B-cell chronic lymphocytic leukemia, Richter transformation, follicular lymphoma, mantle cell lymphoma |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04728893 |
Apr 2021 → Jan 2029 expected |
Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT06136559 |
Dec 2023 → Sep 2032 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05947851 |
Aug 2023 → Jun 2032 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05624554 |
Mar 2023 → May 2027 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|